D. E. Shaw & Co., Inc. Infinity Pharmaceuticals, Inc. Transaction History

D. E. Shaw & Co., Inc.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.59 - $1.7 $447,841 - $1.29 Million	-759,054 Reduced 95.46%	36,133 $43,000
Q2 2022 Aug 15, 2022	SELL	$0.49 - $1.2 $159,336 - $390,211	-325,176 Reduced 29.02%	795,187 $502,000
Q1 2022 May 16, 2022	SELL	$0.85 - $2.4 $394,482 - $1.11 Million	-464,097 Reduced 29.29%	1,120,363 $1.28 Million
Q4 2021 Feb 14, 2022	SELL	$1.86 - $3.36 $1.2 Million - $2.16 Million	-643,074 Reduced 28.87%	1,584,460 $3.57 Million
Q3 2021 Nov 15, 2021	BUY	$1.52 - $3.82 $3.22 Million - $8.1 Million	2,119,509 Added 1962.05%	2,227,534 $7.62 Million
Q2 2021 Aug 16, 2021	BUY	$2.66 - $3.47 $287,346 - $374,846	108,025 New	108,025 $323,000
Q2 2019 Aug 14, 2019	SELL	$1.43 - $1.87 $14,600 - $19,092	-10,210 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$1.18 - $1.91 $12,047 - $19,501	10,210 New	10,210 $19,000
Q4 2018 Feb 14, 2019	SELL	$1.01 - $2.78 $19,942 - $54,891	-19,745 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$1.72 - $2.71 $33,961 - $53,508	19,745 New	19,745 $54,000
Q4 2017 Feb 14, 2018	SELL	$1.22 - $3.73 $514,283 - $1.57 Million	-421,544 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$0.94 - $1.35 $396,251 - $569,084	421,544	421,544 $561,000

1.26M

Ticker INFI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 89,277,904
Description
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of met...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.